Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits...
Halozyme (HALO) has been the top stock on our watch list for a few weeks now, and while it’s not immune to the market’s wiggles, the stock has actually been rounding out a big launching pad as the indexes implode, observes Mike Cintolo, editor of Cabot Growth Investor. For fur...
Danish biotech firm Genmab A/S (GMAB) said on Thursday it had begun a new arbitration and was seeking an award of $405M under its license agreement with Johnson & Johnson's (JNJ) unit Janssen Biotech for cancer drug, Darzalex. Genmab is locked in a legal battle with JNJ ove...
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and ch...
Halozyme Therapeutics (NASDAQ:HALO) has launched its oral testosterone therapy Tlando. The drug was approved by the U.S. FDA on March 28. Tlando marks Halozyme's second hormone replacement therapy. Xyosted, which is given weekly via subcutaneous auto-injector, was approved in 2018. See why Se...
Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy PR Newswire SAN DIEGO , June 7, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the commercial laun...
One of the largest tech deals in M&A history was announced last week. Chipmaker Broadcom entered into an agreement to acquire VMware for $69 billion in a cash or stock deal. Broadcom's acquisition of VMware will be reviewed by either the FTC or the DOJ, the Committee on Foreig...
Halozyme Therapeutics announced that they are acquiring Antares Pharma at $5.60 per share in cash, for a total of ~$960M. The deal is expected to close in 1H of 2022. Antares develops products utilizing their drug delivery systems and has multiple royalty streams for their auto-inject...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Halozyme Therapeutics, Inc. (HALO) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mike DiFiore - Eve...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...